373110.KQ
Xcell Therapeutics, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 998.00
−4.04%Year over year
Reported trailing growth
- Revenue
- +193.7%
- EBITDA
- -53.5%
- EBIT
- -6.4%
- EPS
- +23.4%
- Free cash flow
- -9.3%
- Operating cash flow
- -27.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +24.1%
- EBITDA
- -16.9%
- EBIT
- -16.3%
- Net income
- -14.5%
- EPS
- -7.3%
- Free cash flow
- -36.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026